ARKG Holdings of Nurix Pharmaceuticals (NRIX) - Updated Daily
Join Premium Plan
Trades of NRIX Made In ARKG
Why do the number of shares of a company held in an ARK ETF go up or down even when no trades are reported?
The Bucket ReportSubscribe to get all the important numbers from the financial markets delivered to your inbox every trading day 📫
Key Statistics
Statistics
Clinical Trials (0)
Institutional Ownership Trends
News That Matters
| 🕵🏼Found In | 🏷Last Price |
|---|---|
| ARKG | $14.22 |
| ⚖️Weighting | 🧢Market Cap |
| 0.15% | $636.17m |
| 🏋🏿♂️Weight Rank In ARKG | 🧮Price to Sales |
| 47 | 21.38 |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 147 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
| $27.52 | 0.87% |
| Description | |
|---|---|
| Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. | |
| Website | |
| www.nurixtx.com |
Research Notes and Commentary for NRIX
No Research Notes Found for NRIX